A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours.

Trial Profile

A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Apr 2014

At a glance

  • Drugs L19-IL2 fusion protein (Primary)
  • Indications Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Philogen
  • Most Recent Events

    • 03 Jul 2013 New source identified and integrated (German Clinical Trials Register; DRKS00004061).
    • 06 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top